Business Description
BeiGene Ltd
NAICS : 325412
SIC : 2834
ISIN : US07725L1026
Share Class Description:
BGNE: ADRCompare
Compare
Traded in other countries / regions
BGNE.USA688235.China06160.Hong Kong49B.GermanyB1GN34.BrazilBGNE.Mexico IPO Date
2016-02-03Description
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.38 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.32 | |||||
| Debt-to-EBITDA | -1.38 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 4.43 | |||||
| Beneish M-Score | -1.97 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 85.3 | |||||
| 3-Year EBITDA Growth Rate | 18 | |||||
| 3-Year EPS without NRI Growth Rate | 24.3 | |||||
| 3-Year FCF Growth Rate | 2.4 | |||||
| 3-Year Book Growth Rate | -7 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 30.54 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 19.03 | |||||
| 9-Day RSI | 26.9 | |||||
| 14-Day RSI | 33.6 | |||||
| 6-1 Month Momentum % | 46.53 | |||||
| 12-1 Month Momentum % | 18.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.98 | |||||
| Quick Ratio | 1.75 | |||||
| Cash Ratio | 1.34 | |||||
| Days Inventory | 305.21 | |||||
| Days Sales Outstanding | 45.53 | |||||
| Days Payable | 253.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.4 | |||||
| Shareholder Yield % | -1.25 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 84.98 | |||||
| Operating Margin % | -28.62 | |||||
| Net Margin % | -16.91 | |||||
| FCF Margin % | -43.8 | |||||
| ROE % | -14.69 | |||||
| ROA % | -9.21 | |||||
| ROIC % | -39.17 | |||||
| 3-Year ROIIC % | 27.56 | |||||
| ROC (Joel Greenblatt) % | -61.5 | |||||
| ROCE % | -22.02 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.57 | |||||
| PB Ratio | 6.19 | |||||
| Price-to-Tangible-Book | 6.29 | |||||
| EV-to-EBIT | -23.9 | |||||
| EV-to-Forward-EBIT | -1840.79 | |||||
| EV-to-EBITDA | -26.79 | |||||
| EV-to-Forward-EBITDA | 263.78 | |||||
| EV-to-Revenue | 6.84 | |||||
| EV-to-Forward-Revenue | 4.36 | |||||
| EV-to-FCF | -15.61 | |||||
| Price-to-Net-Current-Asset-Value | 13.95 | |||||
| Price-to-Net-Cash | 84.46 | |||||
| Earnings Yield (Greenblatt) % | -4.18 | |||||
| FCF Yield % | -5.89 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BGNE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BeiGene Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,096.535 | ||
| EPS (TTM) ($) | -5.2 | ||
| Beta | 0.68 | ||
| Volatility % | 39.16 | ||
| 14-Day RSI | 33.6 | ||
| 14-Day ATR ($) | 7.425509 | ||
| 20-Day SMA ($) | 210.8805 | ||
| 12-1 Month Momentum % | 18.58 | ||
| 52-Week Range ($) | 126.9681 - 248.16 | ||
| Shares Outstanding (Mil) | 106.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BeiGene Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BeiGene Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
BeiGene Ltd Frequently Asked Questions
What is BeiGene Ltd(BGNE)'s stock price today?
The current price of BGNE is $196.57. The 52 week high of BGNE is $248.16 and 52 week low is $126.97.
When is next earnings date of BeiGene Ltd(BGNE)?
The next earnings date of BeiGene Ltd(BGNE) is 2024-11-15 Est..
Does BeiGene Ltd(BGNE) pay dividends? If so, how much?
BeiGene Ltd(BGNE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers